drugset / Trial / NCT01119287

Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis

NCT01119287

Phase 4 Completed 180 enrolled Alcon Research
RandomizedParallel-groupDouble-blindDiagnostic

Summary

The purpose of this study was to evaluate the efficacy of Maxidex and Patanol compared to placebo in patients with allergic conjunctivitis when exposed to controlled allergen levels in an Environmental Exposure Chamber (EEC).

Timeline

Start
2010-03
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 0.1 % Other
Subject Olopatadine Other / unclassified 0.1 % Other

Indications